Greenwich Biosciences

What Greenwich Biosciences does

Greenwich Biosciences is the US operating subsidiary of Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ), founded in 2013 and headquartered in Carlsbad, California. The company's commercial focus is the US marketing and distribution of Epidiolex (cannabidiol), an FDA-approved prescription medicine indicated for seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex in patients one year of age and older. Greenwich Biosciences was originally established as the US arm of GW Pharmaceuticals and was acquired by Jazz Pharmaceuticals in 2021 for approximately $7.2 billion, after which Epidiolex has been marketed through the Greenwich Biosciences entity in the United States.

The company operates as a wholly-owned subsidiary within Jazz's broader biopharmaceutical platform, which spans rare diseases, sleep disorders (Xywav, Xyrem, Sunosi), and oncology (Zepzelca, Vyxeos, Rylaze, Defitelio). Greenwich distributes Epidiolex through specialty pharmacy channels and healthcare provider prescriptions, generating revenue through product sales rather than licensing or subscription models. Pricing is not publicly disclosed and varies by indication, payer coverage, and patient assistance programs.

As a subsidiary of a public biopharmaceutical company, Greenwich Biosciences benefits from Jazz's global commercial infrastructure, corporate development function (which actively pursues biotech licensing and co-development — exemplified by the 2026 AbCellera collaboration on T-cell engaging multispecific antibodies), and continued investment in clinical data generation, including Phase 3 trials such as Zepzelca's LAGOON study and real-world evidence presentations at SLEEP 2026. The strategic role of Greenwich Biosciences within the Jazz enterprise is to anchor the US neuroscience and rare-disease commercial footprint, with Epidiolex serving as the franchise's flagship asset.

Name

Greenwich Biosciences

Legal name

Jazz Pharmaceuticals, Inc.

Website

https://greenwichbiosciences.com

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

251–500 employees

Short description

Greenwich Biosciences is the US operating subsidiary of Jazz Pharmaceuticals, commercializing Epidiolex (cannabidiol), an FDA-approved prescription medicine for seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.

Ownership category

akta.pro rank

Product category

Cannabinoid-based Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Cannabidiol medicines
• Rare disease therapeutics
• Epilepsy treatments
• Prescription pharmaceuticals
• Cannabinoid-based drugs

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Marketing or Sales, Technology or R&D, Supply Chain, Personnel

Revenue model

1. Pharmaceutical Product Sales: Jazz Pharmaceuticals generates revenue through the sale of proprietary pharmaceutical products including Epidiolex, Xywav, Xyrem, Defitelio, Rylaze, Vyxeos, and Zepzelca. These are prescription medicines distributed through pharmacy channels and specialty distributors.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Greenwich Biosciences is the U.S. operating subsidiary that markets Epidiolex (cannabidiol), a prescription CBD-based medicine, for the treatment of seizures associated with rare epilepsy syndromes. The company serves as Jazz Pharmaceuticals' U.S. commercial vehicle for cannabinoid-derived pharmaceutical products developed originally by GW Pharmaceuticals.

Product overview

Jazz Pharmaceuticals is a global biopharmaceutical company offering a portfolio of prescription medicines. The company's products include treatments for rare diseases, sleep disorders, and oncology. Key products include Epidiolex (cannabidiol), Xyrem (sodium oxybate), Xywav (oxyates oral solution), Defitelio (defibrotide sodium), Rylaze (asparaginase), Vyxeos (daunorubicin/cytarabine), Zepzelca (lurbinectedin), and Sunosi. The company focuses on advancing care in rare diseases and has programs in sleep medicine and targeted cancer care including HER2-expressing cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• Epidiolex (cannabidiol)

Quantifiable outcome

• Demonstrated real-world impact of Xywav on patient outcomes across narcolepsy and idiopathic hypersomnia

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• AbCelleracoreStrategic or Co-development Partner · 17 June 2026Jazz Pharmaceuticals and AbCellera announced a collaboration to discover next-generation T-cell engaging multispecific antibodies for cancer treatment. This strategic partnership leverages AbCellera's antibody discovery platform and Jazz's oncology development expertise to advance novel multispecific antibody therapeutics.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Jazz Pharmaceuticals: Parent company of Greenwich Biosciences and principal marketer of Epidiolex in the US. Operates the same neuroscience/CNS specialty pharma franchise including Xywav, Xyrem, and other rare disease assets, making it the most directly comparable entity.
• GW Pharmaceuticals: Pre-acquisition parent of Greenwich Biosciences; original developer of Epidiolex and cannabis-derived prescription medicines. Same product and therapeutic area as Greenwich, now consolidated into Jazz.
• Supernus Pharmaceuticals: Specialty CNS pharmaceutical company with a portfolio that includes treatments for epilepsy and CNS conditions, addressing the same neurology prescribers and patient populations as Epidiolex.
• SK Life Science: Specialty pharmaceutical company focused on epilepsy treatment (XCOPRI/cenobamate), targeting the same neurology prescribers and rare seizure patient populations as Greenwich's Epidiolex.
• Jazz Pharmaceuticals (EU division): Jazz's European operations, including the legacy GW Pharma UK entity, market Epidiolex outside the US. Operates the same cannabinoid-based neurology franchise as Greenwich with geographic differentiation.

Broad incumbents

• UCB: Global biopharmaceutical company with a leading anti-epileptic franchise (Keppra, Vimpat, Briviact). Competes in the same physician-specialty and patient markets as Greenwich for seizure disorders but operates at much greater scale and scope.
• Lundbeck: Specialty CNS-focused global pharmaceutical company with neurology/psychiatry portfolio. Indirect competitor in the broader CNS specialty space serving overlapping neurology prescribers.

Emerging players

• Zynerba Pharmaceuticals: Clinical-stage cannabinoid therapeutics developer focused on rare neurological and psychiatric conditions; represents a potential future competitor to Epidiolex in CBD-based neurology therapeutics.
• Tilray Brands: Cannabis company with branded pharmaceutical-grade cannabis products. Comparable on cannabinoid-based therapeutic platforms targeting CNS indications, though primarily a recreational/consumer cannabis business.
• Marinus Pharmaceuticals: Specialty pharma focused on seizure disorders (Ztalmy/ganaxolone for CDKL5 deficiency disorder). Targets rare pediatric epilepsy populations with overlapping prescriber base as Epidiolex.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/greenwichbio

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Greenwich Biosciences